0

Close
 
2022
Antiemetics Market

Antiemetics Market

by Drug Type (Antihistamines, Serotonin Receptor Antagonists, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Anticholinergics, Other Drug Types), by Application (Chemotherapy, Post Operative Surgery, Pregnancy and Gatroenteritis, Other Applications), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2022-2031

LS : Pharmaceuticals
Report Code: A00336
Nov 2022 | Pages: 260
Tables: 131
Charts: 63

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

Antiemetics Market Research, 2031

The global antiemetics market was valued at $2.3 billion in 2021, and is projected to reach $4.1 billion by 2031, growing at a CAGR of 6.1% from 2022 to 2031. The drugs or medications which helps to prevent and treat conditions such as nausea, and vomiting are referred as antiemetic drugs. Emesis can be caused due to various ailments including vertigo and motion sickness. Also chemotherapies are associated with the side effects such as nausea and vomiting which can be treated or prevented with these antiemetics. Furthermore, these antiemetic drugs belongs to different class such as serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists and others and have wide applications in the healthcare sector. These drugs can also be used to treat vomiting caused by several medical conditions, including gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others.

According to Cancer Statistics by the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the disease, which highlights the higher utilization of the chemotherapy treatment. Chemotherapy-induced nausea and vomiting is the most severe symptoms for cancer patients receiving the chemotherapy which can further lead to metabolic disorders, dehydration, nutritional depletion and esophageal tears, and can affect the quality of life and interfere with treatment schedules. Thus, this highlights the need for the antiemetic treatment for the patient, leading to the expansion of the market. For instance, the most commonly used treatment for chemotherapy-induced nausea and vomiting is a combination of serotonin (5-HT3) receptor antagonists, a steroid (dexamethasone), and a neurokinin-1 (NK1) receptor antagonist (aprepitant).

Furthermore, nausea and vomiting during the pregnancy is a common condition which is known as “morning sickness”. Nausea and vomiting of pregnancy usually doesn't harm the fetus, but it can affect normal everyday activities. American Academy of Family Physicians (AAFP) states that, nausea and vomiting of pregnancy affects nearly 75% of pregnant women and about 1% of women develop hyper-emesis gravidarum, which may result in adverse outcomes for the mother and fetus. In some cases, morning sickness lasts much longer, and antiemetic drugs are extremely helpful in treating such conditions. Thus, this highlights the demand for the antiemetics during the pregnancy propelling the growth of the antiemetics market.

Also the rise in prevalence of the vertigo and vestibular neuritis which causes symptoms as dizziness, balance problems, nausea and vomiting, will contribute to the rise in demand of the antiemetic drugs. Also, the rise in the prevalence of the gastroenteritis, food poisoning, and vomiting and nausea associated diseases boost the antiemetics market growth.

In addition, the primary driving factors for the market growth include the patent expiration of various drugs, launching of more cost-effective generic substitutes, and rise in the investments by the key market players in manufacturing of the antiemetic drug molecules.

Furthermore, less knowledge regarding the appropriate dosage, strength and usage are expected to hamper the market growth. However, increase in healthcare expenditure and rising research and development activities, will provide large antiemetics market opportunity for investment to the market players during the antiemetics market forecast.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global antiemetics market, as a medical method to decrease SARS-CoV-2-induced nausea and vomiting and balance negative effects from drugs in use. Furthermore, the COVID 19 vaccination caused various side effects in the individuals which include the nausea and vomiting, and this also propelled the growth of the market.

Antiemetics Market

The antiemetics market is segmented on the basis of drug type, application, distribution channel and region. On the basis of drug type, the market is bifurcated into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and other drug type. On the basis of application, the market is segmented into chemotherapy, post operative surgery, pregnancy and gastroenteritis and other applications. On the basis of distribution channel, the market is categorized into retail pharmacies, hospital pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

By drug type, the serotonin receptor antagonists segment dominated the antiemetics market size in 2021, and is estimated to be the fastest growing segment, with a high CAGR of 7.1% owing to the rise in the demand for Ondansetron and Gravisetron for preventing vomiting and nausea mostly after surgical procedures.

Antiemetics Market
By Drug Type

Your browser does not support the canvas element.

By drug type, the serotonin receptor antagonists segment generated maximum revenue in 2021

Get more information on this report : Request Sample Pages

Depending on the application, the chemotherapy segment dominated the antiemetics market size in 2021, due to the rise in the cancer cases and subsequent rise in the chemotherapies for the treatment whereas the post operative surgery segment is estimated to grow with a CAGR of 6.7% in the forecasted period due rise in the number of surgeries around the globe due to the recent advancements and developments in the surgical procedures which causes the shift of the population towards surgeries as a treatment option.

Antiemetics Market
By Application

Your browser does not support the canvas element.

Depending on the application, the chemotherapy segment dominated the market in 2021

Get more information on this report : Request Sample Pages

Depending on distribution channel, the retail pharmacies segment owned the largest share of the antiemetics market share in 2021, whereas the online pharmacies is expected to grow at the highest CAGR of 7.7% during the forecast period due to the rise in the adoption of the smart phones, heavy discounts and offers, doorstep delivery and other advantages of the online pharmacies.

Antiemetics Market
By Distribution Channel

Your browser does not support the canvas element.

Depending on distribution channel, the retail pharmacies segment owned the largest share of the market in 2021

Get more information on this report : Request Sample Pages

Region wise, North America acquired a major antiemetics market share in the year 2021, and registered the growth at a CAGR of 5.1%. However, Asia-Pacific is expected to witness the highest growth rate for the antiemetics market throughout the forecast period with a CAGR of 7.8%. The major factors that drive the growth of the antiemetics market is the elevating healthcare demand for highly potent drug, and adoption of radiation therapy for the cancer treatment. Moreover, availability of excessive raw material in this region and also, the rise in market players investing in research and development are leveraging the antiemetics industry.

Antiemetics Market
By Region

2031
North America 
Europe
Asia-Pacific
LAMEA

Region wise, North America acquired a major share in the year 2021

Get more information on this report : Request Sample Pages

Some of the major companies that operate in the global antiemetics industry are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiemetics market analysis from 2021 to 2031 to identify the prevailing antiemetics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antiemetics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antiemetics market trends, key players, market segments, application areas, and market growth strategies.

 Antiemetics Market Report Highlights

Aspects Details
Market Size By 2031 USD 4.1 billion
Growth Rate CAGR of 6.1%
Forecast period 2021 - 2031
Report Pages 260
By Drug Type
  • Antihistamines
  • Serotonin Receptor Antagonists
  • Dopamine Receptor Antagonists
  • Neurokinin Receptor Antagonists
  • Anticholinergics
  • Other Drug Types
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
By Application
  • Chemotherapy
  • Post Operative Surgery
  • Pregnancy and Gatroenteritis
  • Other Applications
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest Of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest Of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest Of LAMEA)
Key Market Players Novartis AG, Merck & Co. Inc, Eisai Co. Ltd, Teva Pharmaceuticals, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Cipla, Johnson & Johnson, Pfizer Inc, Dr. Reddy’s Laboratories Ltd

Analyst Review

This section provides opinions of the top-level CXOs operating in the global antiemetics market. According to the insights of the CXOs, the global antiemetics market is expected to exhibit high growth potential attributable to factors such as rise in in R&D activities in pharmaceutical industry for manufacturing of the antiemetic medicines; increase in prevalence of cancer and gastroenteritis diseases and surge in number advancements in the diagnosis and treatment. Furthermore, the antiemetics market has gained interest of many pharmaceutical companies, owing to surge in demand for the medications due to rise in the patient pool in the regions such as Asia-Pacific and LAMEA. Moreover, increase in number of geriatric patients, who are highly prone to viral and bacterial infections due to poor immunity, notably contributes toward the growth of the market.

 

The CXOs further added that North America is expected to witness the highest growth, in terms of revenue, rise in incidences of chronic illness, high adoption rate, high prevalence of unmet medical needs, robust R&D infrastructure for life science researches, presence of key players, and advancements in healthcare investments and Asia-Pacific is expected to register highest growth during the forecast period, due to the continuous government support for pharmaceutical and R&D, increase in public–private investments, and rise in number of research activities in the healthcare sector for improved and efficient treatment. In addition, abundance of pipeline products is anticipated to drive the market growth. In addition, Asia-Pacific possesses high potential for the growth of antiemetics market due to the presence of high population base and untapped market opportunities.

 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. High bargaining power of suppliers

      • 3.3.2. High threat of new entrants

      • 3.3.3. High threat of substitutes

      • 3.3.4. Hih intensity of rivalry

      • 3.3.5. Moderate bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. High prevalence of cancer and subsequent rise in chemotherapies
        • 3.4.1.2. Rise in prevalence of gastroenteritis and other gastric issues
        • 3.4.1.3. Rise in prevalence of vertigo

      • 3.4.2. Restraints

        • 3.4.2.1. Less awareness regarding antiemetic drugs among population

      • 3.4.3. Opportunities

        • 3.4.3.1. Increase in healthcare expenditure

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Antihistamines

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Serotonin Receptor Antagonists

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

    • 4.4. Dopamine Receptor Antagonists

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast, by region

      • 4.4.3. Market share analysis by country

    • 4.5. Neurokinin Receptor Antagonists

      • 4.5.1. Key market trends, growth factors and opportunities

      • 4.5.2. Market size and forecast, by region

      • 4.5.3. Market share analysis by country

    • 4.6. Anticholinergics

      • 4.6.1. Key market trends, growth factors and opportunities

      • 4.6.2. Market size and forecast, by region

      • 4.6.3. Market share analysis by country

    • 4.7. Other Drug Types

      • 4.7.1. Key market trends, growth factors and opportunities

      • 4.7.2. Market size and forecast, by region

      • 4.7.3. Market share analysis by country

  • CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Chemotherapy

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Post Operative Surgery

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

    • 5.4. Pregnancy and Gatroenteritis

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast, by region

      • 5.4.3. Market share analysis by country

    • 5.5. Other Applications

      • 5.5.1. Key market trends, growth factors and opportunities

      • 5.5.2. Market size and forecast, by region

      • 5.5.3. Market share analysis by country

  • CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Retail Pharmacies

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Hospital Pharmacies

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

    • 6.4. Online Pharmacies

      • 6.4.1. Key market trends, growth factors and opportunities

      • 6.4.2. Market size and forecast, by region

      • 6.4.3. Market share analysis by country

  • CHAPTER 7: ANTIEMETICS MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Drug Type

      • 7.2.3. Market size and forecast, by Application

      • 7.2.4. Market size and forecast, by Distribution Channel

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Drug Type
          • 7.2.5.1.3. Market size and forecast, by Application
          • 7.2.5.1.4. Market size and forecast, by Distribution Channel
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Drug Type
          • 7.2.5.2.3. Market size and forecast, by Application
          • 7.2.5.2.4. Market size and forecast, by Distribution Channel
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Drug Type
          • 7.2.5.3.3. Market size and forecast, by Application
          • 7.2.5.3.4. Market size and forecast, by Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Drug Type

      • 7.3.3. Market size and forecast, by Application

      • 7.3.4. Market size and forecast, by Distribution Channel

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Drug Type
          • 7.3.5.1.3. Market size and forecast, by Application
          • 7.3.5.1.4. Market size and forecast, by Distribution Channel
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Drug Type
          • 7.3.5.2.3. Market size and forecast, by Application
          • 7.3.5.2.4. Market size and forecast, by Distribution Channel
        • 7.3.5.3. UK
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Drug Type
          • 7.3.5.3.3. Market size and forecast, by Application
          • 7.3.5.3.4. Market size and forecast, by Distribution Channel
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Drug Type
          • 7.3.5.4.3. Market size and forecast, by Application
          • 7.3.5.4.4. Market size and forecast, by Distribution Channel
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Drug Type
          • 7.3.5.5.3. Market size and forecast, by Application
          • 7.3.5.5.4. Market size and forecast, by Distribution Channel
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Drug Type
          • 7.3.5.6.3. Market size and forecast, by Application
          • 7.3.5.6.4. Market size and forecast, by Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Drug Type

      • 7.4.3. Market size and forecast, by Application

      • 7.4.4. Market size and forecast, by Distribution Channel

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. China
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Drug Type
          • 7.4.5.1.3. Market size and forecast, by Application
          • 7.4.5.1.4. Market size and forecast, by Distribution Channel
        • 7.4.5.2. Japan
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Drug Type
          • 7.4.5.2.3. Market size and forecast, by Application
          • 7.4.5.2.4. Market size and forecast, by Distribution Channel
        • 7.4.5.3. India
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Drug Type
          • 7.4.5.3.3. Market size and forecast, by Application
          • 7.4.5.3.4. Market size and forecast, by Distribution Channel
        • 7.4.5.4. Australia
          • 7.4.5.4.1. Key market trends, growth factors and opportunities
          • 7.4.5.4.2. Market size and forecast, by Drug Type
          • 7.4.5.4.3. Market size and forecast, by Application
          • 7.4.5.4.4. Market size and forecast, by Distribution Channel
        • 7.4.5.5. South Korea
          • 7.4.5.5.1. Key market trends, growth factors and opportunities
          • 7.4.5.5.2. Market size and forecast, by Drug Type
          • 7.4.5.5.3. Market size and forecast, by Application
          • 7.4.5.5.4. Market size and forecast, by Distribution Channel
        • 7.4.5.6. Rest of Asia-Pacific
          • 7.4.5.6.1. Key market trends, growth factors and opportunities
          • 7.4.5.6.2. Market size and forecast, by Drug Type
          • 7.4.5.6.3. Market size and forecast, by Application
          • 7.4.5.6.4. Market size and forecast, by Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Drug Type

      • 7.5.3. Market size and forecast, by Application

      • 7.5.4. Market size and forecast, by Distribution Channel

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Brazil
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Drug Type
          • 7.5.5.1.3. Market size and forecast, by Application
          • 7.5.5.1.4. Market size and forecast, by Distribution Channel
        • 7.5.5.2. Saudi Arabia
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Drug Type
          • 7.5.5.2.3. Market size and forecast, by Application
          • 7.5.5.2.4. Market size and forecast, by Distribution Channel
        • 7.5.5.3. South Africa
          • 7.5.5.3.1. Key market trends, growth factors and opportunities
          • 7.5.5.3.2. Market size and forecast, by Drug Type
          • 7.5.5.3.3. Market size and forecast, by Application
          • 7.5.5.3.4. Market size and forecast, by Distribution Channel
        • 7.5.5.4. Rest of LAMEA
          • 7.5.5.4.1. Key market trends, growth factors and opportunities
          • 7.5.5.4.2. Market size and forecast, by Drug Type
          • 7.5.5.4.3. Market size and forecast, by Application
          • 7.5.5.4.4. Market size and forecast, by Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2021

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. GlaxoSmithKline Plc

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Business performance

    • 9.2. F. Hoffmann-La Roche Ltd

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

      • 9.2.6. Business performance

    • 9.3. Novartis AG

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

    • 9.4. Pfizer Inc

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

      • 9.4.6. Business performance

    • 9.5. Merck & Co. Inc

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

      • 9.5.6. Business performance

    • 9.6. Dr. Reddy’s Laboratories Ltd

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

      • 9.6.6. Business performance

    • 9.7. Cipla

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

    • 9.8. Johnson & Johnson

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Business performance

    • 9.9. Teva Pharmaceuticals

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

    • 9.10. Eisai Co. Ltd

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

  • LIST OF TABLES

  • TABLE 01. GLOBAL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 02. ANTIEMETICS MARKET FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
    TABLE 03. ANTIEMETICS MARKET FOR SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
    TABLE 04. ANTIEMETICS MARKET FOR DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
    TABLE 05. ANTIEMETICS MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
    TABLE 06. ANTIEMETICS MARKET FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
    TABLE 07. ANTIEMETICS MARKET FOR OTHER DRUG TYPES, BY REGION, 2021-2031 ($MILLION)
    TABLE 08. GLOBAL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 09. ANTIEMETICS MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
    TABLE 10. ANTIEMETICS MARKET FOR POST OPERATIVE SURGERY, BY REGION, 2021-2031 ($MILLION)
    TABLE 11. ANTIEMETICS MARKET FOR PREGNANCY AND GATROENTERITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 12. ANTIEMETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
    TABLE 13. GLOBAL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 14. ANTIEMETICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 15. ANTIEMETICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 16. ANTIEMETICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 17. ANTIEMETICS MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 18. NORTH AMERICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 19. NORTH AMERICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 20. NORTH AMERICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 21. NORTH AMERICA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 22. U.S. ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 23. U.S. ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 24. U.S. ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 25. CANADA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 26. CANADA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 27. CANADA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 28. MEXICO ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 29. MEXICO ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 30. MEXICO ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 31. EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 32. EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 33. EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 34. EUROPE ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 35. GERMANY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 36. GERMANY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 37. GERMANY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 38. FRANCE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 39. FRANCE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 40. FRANCE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 41. UK ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 42. UK ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 43. UK ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 44. ITALY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 45. ITALY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 46. ITALY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 47. SPAIN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 48. SPAIN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 49. SPAIN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 50. REST OF EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 51. REST OF EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 52. REST OF EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 53. ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 54. ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 55. ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 56. ASIA-PACIFIC ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 57. CHINA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 58. CHINA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 59. CHINA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 60. JAPAN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 61. JAPAN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 62. JAPAN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 63. INDIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 64. INDIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 65. INDIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 66. AUSTRALIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 67. AUSTRALIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 68. AUSTRALIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 69. SOUTH KOREA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 70. SOUTH KOREA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 71. SOUTH KOREA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 72. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 73. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 74. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 75. LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 76. LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 77. LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 78. LAMEA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 79. BRAZIL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 80. BRAZIL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 81. BRAZIL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 82. SAUDI ARABIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 83. SAUDI ARABIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 84. SAUDI ARABIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 85. SOUTH AFRICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 86. SOUTH AFRICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 87. SOUTH AFRICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 88. REST OF LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 89. REST OF LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 90. REST OF LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 91. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
    TABLE 92. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
    TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
    TABLE 94. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
    TABLE 95. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
    TABLE 96. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
    TABLE 97. F. HOFFMANN-LA ROCHE LTD: PRODUCT SEGMENTS
    TABLE 98. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
    TABLE 99. NOVARTIS AG: KEY EXECUTIVES
    TABLE 100. NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 101. NOVARTIS AG: PRODUCT SEGMENTS
    TABLE 102. NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 103. PFIZER INC: KEY EXECUTIVES
    TABLE 104. PFIZER INC: COMPANY SNAPSHOT
    TABLE 105. PFIZER INC: PRODUCT SEGMENTS
    TABLE 106. PFIZER INC: PRODUCT PORTFOLIO
    TABLE 107. MERCK & CO. INC: KEY EXECUTIVES
    TABLE 108. MERCK & CO. INC: COMPANY SNAPSHOT
    TABLE 109. MERCK & CO. INC: PRODUCT SEGMENTS
    TABLE 110. MERCK & CO. INC: SERVICE SEGMENTS
    TABLE 111. MERCK & CO. INC: PRODUCT PORTFOLIO
    TABLE 112. DR. REDDY’S LABORATORIES LTD: KEY EXECUTIVES
    TABLE 113. DR. REDDY’S LABORATORIES LTD: COMPANY SNAPSHOT
    TABLE 114. DR. REDDY’S LABORATORIES LTD: PRODUCT SEGMENTS
    TABLE 115. DR. REDDY’S LABORATORIES LTD: PRODUCT PORTFOLIO
    TABLE 116. CIPLA: KEY EXECUTIVES
    TABLE 117. CIPLA: COMPANY SNAPSHOT
    TABLE 118. CIPLA: PRODUCT SEGMENTS
    TABLE 119. CIPLA: PRODUCT PORTFOLIO
    TABLE 120. JOHNSON & JOHNSON: KEY EXECUTIVES
    TABLE 121. JOHNSON & JOHNSON: COMPANY SNAPSHOT
    TABLE 122. JOHNSON & JOHNSON: PRODUCT SEGMENTS
    TABLE 123. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
    TABLE 124. TEVA PHARMACEUTICALS: KEY EXECUTIVES
    TABLE 125. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
    TABLE 126. TEVA PHARMACEUTICALS: PRODUCT SEGMENTS
    TABLE 127. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
    TABLE 128. EISAI CO. LTD: KEY EXECUTIVES
    TABLE 129. EISAI CO. LTD: COMPANY SNAPSHOT
    TABLE 130. EISAI CO. LTD: PRODUCT SEGMENTS
    TABLE 131. EISAI CO. LTD: PRODUCT PORTFOLIO

  • LIST OF FIGURES

  • FIGURE 1.ANTIEMETICS MARKET SEGMENTATION
    FIGURE 2.ANTIEMETICS MARKET,2021-2031
    FIGURE 3.ANTIEMETICS MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.ANTIEMETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.ANTIEMETICS MARKET,BY DRUG TYPE,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINES ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SEROTONIN RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DOPAMINE RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NEUROKININ RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTICHOLINERGICS ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHER DRUG TYPES ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 19.ANTIEMETICS MARKET,BY APPLICATION,2021(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF POST OPERATIVE SURGERY ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PREGNANCY AND GATROENTERITIS ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHER APPLICATIONS ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 24.ANTIEMETICS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
    FIGURE 28.ANTIEMETICS MARKET BY REGION,2021
    FIGURE 29.U.S. ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 30.CANADA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 31.MEXICO ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 32.GERMANY ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 33.FRANCE ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 34.UK ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 35.ITALY ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 36.SPAIN ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 37.REST OF EUROPE ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 38.CHINA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 39.JAPAN ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 40.INDIA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 41.AUSTRALIA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 42.SOUTH KOREA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 43.REST OF ASIA-PACIFIC ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 44.BRAZIL ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 45.SAUDI ARABIA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 46.SOUTH AFRICA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 47.REST OF LAMEA ANTIEMETICS MARKET,2021-2031($MILLION)
    FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 52.COMPETITIVE DASHBOARD
    FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 54.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
    FIGURE 55.SANOFI.: NET SALES ,($MILLION)
    FIGURE 56.NOVARTIS AG.: NET SALES ,($MILLION)
    FIGURE 57.PFIZER INC.: NET SALES ,($MILLION)
    FIGURE 58.MERCK & CO. INC.: NET SALES ,($MILLION)
    FIGURE 59.DR. REDDY’S LABORATORIES LTD.: NET SALES ,($MILLION)
    FIGURE 60.CIPLA.: NET SALES ,($MILLION)
    FIGURE 61.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
    FIGURE 62.TORRENT PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
    FIGURE 63.ACACIA PHARMA GROUP.: NET SALES ,($MILLION)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The global antiemetics market was valued at $2,251.68 million in 2021, and is projected to reach $4,061.36 million by 2031

A. Key strategies adopted by the key market players to expand their business and their antiemetic product portfolio are the upcoming trends of Antiemetics Market in the world

A. Chemotherapy is the leading application of Antiemetics Market

A. North America is the largest regional market for Antiemetics

A. Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals are the top companies to hold the market share in Antiemetics

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Antiemetics Market

Start reading instantly.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Nov 2023 - Nov 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2023 - Nov 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2023 - Nov 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2023 - Nov 2024)

  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2023 - Nov 2024)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers